肿瘤抗血管生成治疗的Ⅰ～Ⅲ期试验正在广泛进行。已证明肿瘤血管生成与不良预后特征相关。估测血管密度为乳腺癌和大多数其它癌提供独立的预后信息。研究表明,如无新血管生成,肿瘤生长就不能超过1mm~3。现已分离出许多种血管生长因子,包括酸性和碱性成纤维细胞生长因子(FGF)及血管内皮生长因子(VEGF)等,也已识别一些抑制正常血管生成的抗血管生成因子,如thrombospondin、angiostatin、血小板因子4等。 Phase I to III trials of tumor anti-angiogenic therapy are being extensively conducted. It has been demonstrated that tumor angiogenesis is associated with poor prognostic features. Estimating vascular density provides independent prognostic information for breast cancer and most other cancers. Studies have shown that tumor growth cannot exceed 1 mm to 3 without neovascularization. A number of angiogenic factors have been isolated, including acidic and basic fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF), and some antiangiogenic factors that inhibit normal angiogenesis have also been identified, such as thrombospondin, Angiostatin, platelet factor 4, etc.